TMCnet News

Research and Markets: MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes (Myocardial Infarction and Unstable Angina)- Current and Future Players
[May 23, 2013]

Research and Markets: MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes (Myocardial Infarction and Unstable Angina)- Current and Future Players


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/ckfp5l/medipoint) has announced the addition of the "MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players" report to their offering.

MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players

Acute coronary syndrome (ACS (News - Alert)) consists of two major diseases: myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency rooms every year with symptoms such as chest pain, and these patients are typically assessed with in vitro diagnostic cardiac biomarker tests. Emergence of two pipeline biomarker tests, Thermo Scientific's copeptin, and heart-type fatty acid binding protei (H-FABP), will provide further diagnostic options to emergency physicians.

This report identifies the unmet needs in the market, provides an understanding of physician perception of ACS diagnostic cardiac biomarker testing, and future trends. Through our analysis, it is evident that the ACS diagnostic cardiac biomarker testing market is dominated by a single player, but it is expected that pipeline tests will begin to be used in combination with this test. To successfully market new diagnostic tests, companies need to offer tests that address the current unmet needs of current ACS diagnostic cardiac biomarker tests and show advantages in combination with tests currently in the market. This report will identify the opportunities for this technology.

Key Topics Covered:


1 Tables & Figures

2 Introduction

3 Competitive Assessment

  • 3.1 Overview
  • 3.2 Cardiac Troponins
  • 3.3 Creatine Kinase-MB
  • 3.4 Myoglobin
  • 3.5 Point-of-Care

4 Pipeline Products

  • 4.1 Overview
  • 4.2 BAG3 (Biouniversia)
  • 4.3 CAVARISK (Cavadis)
  • 4.4 CardioScore (BG Medicine)
  • 4.5 Circulating Endothelial Cells
  • 4.6 Copeptin (Thermo Scientific)
  • 4.7 Heart-Type Fatty Acid Binding Protein
  • 4.8 MIRISK VP Assessment (Aviir)
  • 4.9 Early Emerging Tests

5 Current and Future Players

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • bioMérieux
  • Mitsubishi (News - Alert) Chemical Medience Corporation
  • Ortho-Clinical Diagnostics
  • Radiometer Medical
  • Randox Laboratories
  • Response Biomedical
  • Roche Diagnostics
  • Siemens (News - Alert) Healthcare
  • Thermo Scientific

6 Appendix

For more information visit http://www.researchandmarkets.com/research/ckfp5l/medipoint


[ Back To TMCnet.com's Homepage ]